RESUMO
Cefaclor, a broad-spectrum semi-synthetic second generation oral cephalosporin with documented activity against many grampositive and gram-negative pathogens, as well as some anaerobes has established a record of efficacy in the management of respiratory tract infections (RTIs). Despite over three decades of widespread use, it remains clinically effective in patients with RTIs, making it competitive with amoxicillin-clavulanate and with macrolides, and fluoroquinolones, including many newer agents used for RTIs. Factors contributing to the efficacy and tolerability of cefaclor include its molecular stability, activity against the most prevalent gram-positive and gram-negative respiratory tract pathogens, rapid absorption, >90% bioavailability and good penetration into respiratory mucosa. When compared to amoxicillin-clavulanate, it is much better tolerated with less gastrointestinal adverse events thus ensuring better patient compliance.